Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
0.6850
-0.0300 (-4.20%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Adial Pharmaceuticals Employees
Adial Pharmaceuticals had 5 employees as of December 31, 2024. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,639,490
Market Cap
4.50M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ADIL News
- 7 weeks ago - Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04 - GlobeNewsWire
- 2 months ago - Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies - GlobeNewsWire
- 2 months ago - Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - GlobeNewsWire
- 3 months ago - Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - GlobeNewsWire
- 5 months ago - Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations - GlobeNewsWire
- 6 months ago - Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - GlobeNewsWire
- 7 months ago - Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - GlobeNewsWire